Rethinking ACS in the ED

ACS 2025

Hamish: Welcome back to The TIME Podcast. I’m Hamish.

Jeremy: And I’m Jeremy.

Hamish: This episode is one we’ve been circling for a while, because it’s uncomfortable in exactly the right way. We’re talking about the 2025 Australian Acute Coronary Syndromes Guidelines — but specifically what they mean for emergency departments, not cardiology conference slides.

Jeremy: And that distinction matters. Because guidelines often land very differently at the front door of the hospital than they do in committee rooms or cath labs.

Hamish: Exactly. Emergency departments aren’t just implementing recommendations — they’re absorbing ambiguity, throughput pressure, staffing gaps, and medico-legal risk, all in real time

Jeremy: And over the last decade, EDs have been quietly trained to manage ACS in a very particular way. Highly protocolised. Troponin-driven. Optimised for speed, standardisation, and auditability.

Hamish: Which worked — to a point. It reduced variation, protected junior staff, and gave systems something measurable to hold onto.

Jeremy: But it also reshaped how we think. We stopped asking “what’s happening physiologically?” and started asking “which pathway does this patient fit into?”

Hamish: And that shift wasn’t accidental. It was a rational response to overcrowding, access block, and the need to move patients safely through increasingly constrained systems.

Jeremy: The problem is that the 2025 guidelines quietly withdraw one of the assumptions those systems were built on — that ACS risk can be cleanly sorted early using standardised rules.

Hamish: Which is why this guideline matters so much to EDs. Not because it introduces new drugs or devices — it doesn’t — but because it destabilises the decision architecture we’ve relied on.

Jeremy: And that destabilisation lands first, and hardest, in emergency departments.

Hamish: Because EDs don’t just implement guidelines. They absorb the consequences when those guidelines require judgment instead of pattern recognition.

Jeremy: And that’s the thread we want to pull on today. Not “what does the guideline say”, but “what does it demand of people working in real ED systems”.

Hamish: And whether those systems are actually prepared to meet that demand.

Hamish: So let’s talk about the centrepiece of the guideline — the move away from equating STEMI with coronary occlusion, toward the broader concept of acute coronary occlusion myocardial infarction.

Jeremy: And I think it’s important to say upfront: this isn’t a new idea clinically. We’ve known for years that not all occlusions declare themselves with classic ST elevation.

Hamish: Right. What’s new isn’t the pathophysiology — it’s the fact that the guideline is asking us to reorganise our thinking around it.

Jeremy: And that’s where I get cautious. Because ED thinking has been deliberately engineered over time to be fast, binary, and defensible.

Hamish: Exactly. STEMI wasn’t just a diagnosis — it was a cognitive shortcut. It told you, instantly, “This is time-critical, escalate now”.

Jeremy: And everything else became, by default, lower urgency. Even when we said “high-risk NSTEMI”, the system didn’t behave like it was time-critical.

Hamish: Because the labels mattered more than the biology.

Jeremy: And ACOMI breaks that. Because now we’re being asked to treat occlusion as the unifying concept rather than ECG criteria.

Hamish: Which sounds elegant — but it removes the clean dividing line that EDs rely on to function.

Jeremy: That’s the key tension. STEMI gave us a socially agreed emergency. Everyone knew what it meant. Everyone accepted the disruption it caused.

Hamish: ACOMI is fuzzier. It lives in probabilities, evolving presentations, and clinical judgment.

Jeremy: And ED systems are not good at probabilities. They’re good at triggers.

Hamish: So what the guideline is really doing is shifting us from a pattern-recognition model to a risk-assessment model — without fully redesigning the systems that support that work.

Jeremy: And that’s where I worry we’re underestimating the impact. Because this isn’t just a change in what clinicians need to know — it’s a change in what they’re allowed to act on.

Hamish: It also changes how we define success. Under the old model, success was “did we activate the cath lab for STEMI fast enough?

Jeremy: Now success is “did we recognise occlusion early enough, even when the signal was ambiguous”.

Hamish: Which is much harder to measure, much harder to audit, and much harder to defend after the fact.

Jeremy: And that’s where I think some of the discomfort is coming from. We’re asking clinicians to operate in a space where the right decision may not be obviously right at the time.

Hamish: But I’d push back slightly. I think EDs already live in that space — we’ve just pretended we don’t by leaning on labels.

Jeremy: That’s fair. But the difference now is that the guideline removes the safety net of pretending the label did the thinking for us.

Hamish: And that’s why this isn’t a cardiology problem. It’s an emergency medicine problem.

Jeremy: Because EDs are the ones who have to decide, in real time, whether this presentation represents occlusion — without the comfort of a binary rule.

Hamish: And crucially, they have to do that before troponin kinetics, before downstream testing, and often before senior backup is easily available.

Jeremy: Which brings us to the uncomfortable question: are our ED systems actually designed to support that kind of judgement — or have we trained them out of it?

Hamish: And that question sits underneath everything else in this guideline.

Jeremy: So if ACOMI destabilises the cognitive model, troponin pathways are where that destabilisation becomes operationally uncomfortable.

Hamish: Because troponin pathways aren’t just diagnostic tools. They’re how modern emergency departments stay afloat.

Jeremy: Exactly. We often talk about them as evidence-based medicine — but in practice, they’re also risk management infrastructure.

Hamish: They reduce variation. They make care auditable. They allow junior clinicians to make defensible decisions in noisy environments.

Jeremy: And they give departments something very powerful: consistency.

Hamish: Consistency that administrators, insurers, and courts understand.

Jeremy: Which is why this guideline’s instruction — “do not apply troponin pathways when occlusion is suspected” — is so disruptive.

Hamish: Because it’s not just saying “don’t do this”. It’s saying “step outside the structure that protects you”.

Jeremy: And that’s where I want to slow things down, because it’s easy to caricature this as clinicians being lazy or over-reliant on tests.

Hamish: But that’s not what’s happening. Troponin pathways were adopted because EDs were drowning.

Jeremy: They were a rational response to crowding, access block, and the need to process large volumes of chest pain safely.

Hamish: The problem is that over time, we stopped treating them as decision support and started treating them as decision replacement.

Jeremy: And that’s where safety theatre creeps in.

Hamish: Explain what you mean by that.

Jeremy: Safety theatre is when a process makes everyone feel safer — clinicians, departments, executives — without actually reducing the risk that matters most.

Hamish: So the pathway is followed, the boxes are ticked, and the outcome feels legitimate.

Jeremy: Even if the underlying pathology hasn’t been addressed.

Hamish: Let’s ground this with a real-world example, because this isn’t theoretical.

Jeremy: Middle-aged patient. Chest discomfort that doesn’t quite read as “classic”. Initial ECG is non-diagnostic. The first troponin is low.

Hamish: They’re placed neatly into a 0/2-hour pathway. Everything behaves the way the pathway predicts.

Jeremy: Pain settles. The second troponin is reassuring. Disposition looks safe.

Hamish: And everyone breathes out. Because the system has done what it’s designed to do.

Jeremy: Except the patient represents the next day with a large infarct.

Hamish: And when you look back, no one violated the pathway. No one ignored a result.

Jeremy: The failure wasn’t an individual error. It was misplaced confidence.

Hamish: The pathway answered the wrong question. It asked, “Is there measurable myocardial injury right now?” — not “Is there evolving coronary occlusion?”

Jeremy: And that distinction matters enormously in early presenters and dynamic disease.

Hamish: This is where I’ll push back slightly, though. Troponin pathways have saved an enormous number of patients from unnecessary admission and harm.

Jeremy: I agree. And I’m not anti-troponin. I’m anti-uncritical use.

Hamish: Because the guideline isn’t saying “abandon pathways”. It’s saying “know when they’re unsafe”.

Jeremy: And that’s a much harder instruction to operationalise than it sounds.

Hamish: Because it requires clinicians to override something that feels objective with something that feels subjective.

Jeremy: And subjectivity is where risk lives — professionally and legally.

Hamish: This is where the moral hazard shows up.

Jeremy: Exactly. If you follow the pathway and miss an occlusion, the harm is delayed and diffused.

Hamish: But if you override the pathway and you’re wrong, the scrutiny is immediate and personal.

Jeremy: That asymmetry trains behaviour. Not consciously — but reliably.

Hamish: So the system quietly incentivises pathway compliance over pathophysiological reasoning.

Jeremy: Which is why simply telling clinicians “don’t apply the pathway in occlusion” is insufficient.

Hamish: Because, unless governance, audit, and leadership back change, the safest move for the individual will still be to follow the algorithm.

Jeremy: And that’s the uncomfortable truth. Troponin pathways didn’t just standardise care — they redistributed risk.

Hamish: And the guideline is now trying to redistribute it back, without always saying who should carry it.

Jeremy: Which sets us up perfectly for the next piece of this — ECG primacy — and why it’s so hard to deliver in real EDs.

Hamish: So if troponin pathways dominate decision-making, the guideline’s answer is to reassert ECG primacy.

Jeremy: Which, on the surface, sounds almost nostalgic. Like we’re being told to just “be better clinicians”.

Hamish: And that’s exactly the trap. ECG primacy doesn’t fail because clinicians can’t read ECGs.

Jeremy: It fails because ED systems are structurally hostile to iterative thinking.

Hamish: Exactly. ECG interpretation isn’t a single event — it’s a process. It evolves with symptoms, time, and physiology.

Jeremy: But ED workflows are built around one-time decisions. One ECG at triage. One troponin set. One disposition moment.

Hamish: Once that first decision is made — especially if it’s “low risk” — the system quietly de-escalates.

Jeremy: Ownership fragments. The patient moves location. Different clinicians rotate through. The sense of urgency dissipates.

Hamish: And no one explicitly decides to stop thinking. It just happens.

Jeremy: This is where the phrase “repeat the ECG” becomes almost meaningless.

Hamish: Because repeating an ECG isn’t just a technical task — it’s a claim of continued concern.

Jeremy: And in crowded EDs, continued concern is expensive. It slows the flow. It complicates disposition. It creates friction.

Hamish: So the system subtly discourages it.

Jeremy: Not overtly. No one says “don’t repeat the ECG”. But everything about the environment says “move on”.

Hamish: This is also where cognitive offloading shows up.

Jeremy: Explain that.

Jeremy: When troponin pathways exist, clinicians unconsciously outsource vigilance to the algorithm.

Jeremy: Right — the thinking becomes, “the pathway will catch it”.

Hamish: Which is a rational adaptation in high-noise environments.

Jeremy: But it means ECG primacy isn’t just forgotten — it’s displaced.

Hamish: And the guideline is asking us to reverse that displacement without changing the conditions that caused it.

Jeremy: That’s the uncomfortable part.

Hamish: Because saying “ECGs matter” is easy. Designing systems that allow ECGs to matter repeatedly is much harder.

Jeremy: And this is where I think the guideline risks being misinterpreted as a skills problem rather than a design problem.

Hamish: es. If departments respond by running more ECG teaching sessions, they’ve missed the point.

Jeremy: The problem isn’t knowledge. It’s ownership.

Hamish: Who is responsible for noticing evolution? Who has the authority to pause the pathway? Who feels protected doing so?

Jeremy: Because without explicit answers, ECG primacy becomes aspirational rather than operational.

Hamish: And that’s how you end up with guidelines that everyone agrees with — but few actually deliver.

Jeremy: Which brings us back to the bigger theme. This guideline isn’t asking clinicians to think harder.

Hamish: It’s asking systems to let them think longer.

Jeremy: And that’s a very different request.

Hamish: Everything we’ve talked about so far — ACOMI, troponin pathways, ECG primacy — converges on one uncomfortable issue.

Jeremy: Who actually carries the risk when guidelines demand judgment rather than compliance?

Hamish: Because on paper, this guideline empowers clinicians.

Jeremy: But in practice, empowerment without protection is just risk transfer.

Hamish: Exactly. The guideline says “use judgment”, but it doesn’t automatically change where liability, scrutiny, and blame sit.

Jeremy: And in most EDs, those things still sit with the individual clinician at the bedside.

Hamish: Which creates a very specific kind of asymmetry.

Jeremy: If you follow the troponin pathway and miss an occlusion, the harm is delayed. It may present hours or days later, often in a different context.

Hamish: The decision becomes hard to locate. It’s distributed across time, teams, and systems.

Jeremy: But if you override the pathway — activate early, escalate without classical criteria — and you’re wrong…

Hamish: The scrutiny is immediate, personal, and often adversarial.

Jeremy: You’re asked to justify why you deviated. Why did you “over-call”? Why did you disrupt the flow?

Hamish: And importantly, that scrutiny happens even if the patient outcome is good.

Jeremy: So the system sends a very clear signal:action carries visible risk, inaction carries hidden risk.

Hamish: That’s not a neutral environment for judgment.

Jeremy: It’s a shaping environment.

Hamish: And clinicians adapt to it, often unconsciously.

Jeremy: They learn which decisions generate emails, meetings, and reviews — and which ones quietly disappear.

Hamish: Over time, that shapes behaviour far more than any guideline wording.

Jeremy: This is where moral injury creeps in.

Hamish: Because clinicians know what the guideline is asking. They can see the occlusion risk. They can feel the discomfort.

Jeremy: But they also know the cost of acting — professionally, reputationally, emotionally.

Hamish: So they carry that tension internally.

Jeremy: And when outcomes are bad, they carry it alone.

Hamish: This is what we mean when we say clinicians become shock absorbers for system failure.

Jeremy: They absorb the force created by mismatches between guidelines, governance, and operational reality.

Hamish: And shock absorbers wear out.

Jeremy: Which is why burnout conversations that ignore governance feel hollow to many clinicians.

Hamish: Because this isn’t about resilience. It’s about load.

Jeremy: And loading without structural support causes damage.

Hamish: So when we talk about redistributing risk, this isn’t an abstract policy discussion.

Jeremy: It’s a concrete question: Who signs off on deviation? Who owns escalation thresholds? Who publicly backs clinicians when judgment is exercised in good faith?

Hamish: If the answer to those questions is “the individual doctor”, then the guideline hasn’t empowered anyone.

Jeremy: It’s just increased the personal cost of doing the right thing.

Hamish: And that’s where well-intentioned guidelines can actually make systems worse.

Jeremy: Not because the ideas are wrong — but because the risk hasn’t moved.

Hamish: This is why implementation matters more than publication.

Jeremy: And why leadership, not education, is the limiting factor here.

Hamish: [Hamish]One of the clearest places the guideline says “stop” is post–cardiac arrest care.

Jeremy: And that’s interesting, because historically this has been an area of maximal reflex.

Hamish: For years, the unspoken assumption was: cardiac arrest equals coronary cause until proven otherwise, and urgent angiography was framed as decisive action.

Jeremy: Which made sense in an era where the evidence was sparse, and the stakes felt existential.

Hamish: But the guideline now says something much more restrained: haemodynamically stable patients without ST elevation after ROSC should not undergo routine emergent coronary angiography.

Jeremy: And it’s worth being very precise about what that means — and what it doesn’t.

Hamish: It doesn’t say there’s no coronary pathology.

Jeremy: And it doesn’t say angiography is never appropriate.

Hamish: What it says is that routine, reflex activation isn’t supported by evidence.

Jeremy: And that’s a profoundly uncomfortable place for emergency clinicians to sit.

Hamish: Because restraint is much harder to defend than escalation.

Jeremy: Especially in the immediate post-arrest period, when uncertainty is at its peak and expectations are intense.

Hamish: Families want certainty. Teams want action. Institutions want to feel decisive.

Jeremy: And the ED clinician is often the first person to say, “We’re not sure yet”.

Hamish: Which can sound like inaction, even when it’s evidence-aligned.

Jeremy: This is where evidence gaps matter.

Hamish: The absence of demonstrated benefit is not the same as demonstrated harm — but it still changes the default.

Jeremy: And that’s hard to communicate in real time.

Hamish: It also changes who owns the risk.

Jeremy: If you activate the cath lab reflexively and the outcome is poor, the decision feels justified by tradition.

Hamish: If you don’t activate, and the outcome is poor, the decision feels personal.

Jeremy: That asymmetry again.

Hamish: And it’s compounded by the fact that neurological prognosis is usually unknown when these decisions are made.

Jeremy: So you’re making irreversible decisions in a space of profound uncertainty.

Hamish: Which is why the guidelines’ restraint language is important — but insufficient on its own.

Jeremy: Because saying “don’t do this routinely” doesn’t solve the relational problem.

Hamish: You still have to negotiate that decision with cardiology, ICU, and families.

Jeremy: Often, in environments where disagreement is visible and emotionally charged.

Hamish: And again, the question becomes: who backs the clinician who chooses restraint?

Jeremy: Is that decision owned collectively, or does it live with the individual at the bedside?

Hamish: If it’s the latter, restraint becomes psychologically unsafe.

Jeremy: And unsafe restraint leads right back to reflex escalation.

Hamish: So post–cardiac arrest care becomes a microcosm of the whole guideline.

Jeremy: Judgement is required, evidence is incomplete, and risk distribution determines behaviour.

Hamish: Which brings us neatly to another space where escalation feels unavoidable — cardiogenic shock.

Hamish: Cardiogenic shock is where all of this becomes unavoidable.

Jeremy: Because shock collapses time, tolerance for uncertainty, and appetite for restraint.

Hamish: In shock, delay feels dangerous. Doing more feels virtuous.

Jeremy: And escalation becomes the default moral position.

Hamish: Which is why the guidelines’ language around cardiogenic shock is so measured.

Jeremy: Culprit-lesion-only intervention. No routine balloon pump. No routine ECMO.

Hamish: Not because these tools never help, but because reflexive use hasn’t delivered consistent benefit.

Jeremy: And because escalation without governance creates its own harm.

Hamish: This is where ED clinicians sit in a very awkward position.

Jeremy: They’re often the first to initiate the shock trajectory — activating teams, starting transfers, committing resources.

Hamish: But they rarely control where that trajectory ends.

Jeremy: Once escalation starts, momentum takes over.

Hamish: And de-escalation becomes politically and emotionally difficult.

Jeremy: Which is why latency matters so much.

Hamish: Explain that.

Jeremy: There’s a window early in shock where decisions shape everything that follows — but evidence, physiology, and prognosis are all incomplete.

Hamish: So clinicians act to avoid missing a narrow opportunity.

Jeremy: But the system doesn’t always distinguish between early appropriate escalation and unnecessary trajectory commitment.

Hamish: And that’s where nuance in the guideline can be lost.

Jeremy: Because nuance doesn’t survive handover well.

Hamish: ED to ICU. ICU to cardiology. Each step adds interpretation, pressure, and expectation.

Jeremy: And once advanced support is in play, withdrawing becomes ethically fraught.

Hamish: Which means initial decisions carry enormous downstream weight.

Jeremy: Yet those decisions are often made by clinicians with the least longitudinal authority.

Hamish: This is another example of risk concentration at the front door.

Jeremy: Exactly. ED clinicians assume responsibility for starting things they can’t stop.

Hamish: The guideline is trying to introduce brakes, but brakes only work if everyone agrees they exist.

Jeremy: Otherwise, restraint looks like indecision.

Hamish: And indecision in the face of shock feels morally wrong.

Jeremy: Which is why escalation culture persists, even when evidence cools enthusiasm.

Hamish: So again, this isn’t a question of knowing the guideline.

Jeremy: It’s a question of whether systems can support measured escalation without punishing caution.

Hamish: And whether ED clinicians are protected when they slow things down.

Jeremy: Because without that protection, shock will always default to “more”.

Hamish: Let’s talk about time targets, because on the surface, they look like the least controversial part of the guideline.

Hamish: Who could argue with faster reperfusion?

Hamish: Exactly. First medical contact–to–device time sounds like a purely clinical aspiration.

Jeremy: But in reality, time targets are never just clinical. They’re political.

Hamish: Explain that.

Jeremy: Time targets decide what a system is willing to prioritise, what it’s willing to fund, and who it’s willing to blame when things go wrong.

Hamish: They turn abstract goals into visible performance.

Jeremy: And visible performance creates pressure.

Hamish: The guideline makes these targets explicit system performance indicators, not aspirational goals.

Jeremy: Which is a big shift. Because once something is a KPI, behaviour changes.

Hamish: Not always in the way you expect.

Jeremy: Exactly. Systems optimise for what’s measured.

Hamish: And when speed becomes the dominant signal, other things get quietly deprioritised.

Jeremy: Like diagnostic uncertainty. Or thoughtful delay. Or stopping to reassess when the picture doesn’t fit neatly.

Hamish: This creates a subtle but powerful tension.

Jeremy: On one hand, delayed reperfusion causes harm. That’s not in dispute.

Hamish: On the other hand, premature activation in ambiguous cases carries its own risks — clinical, resource, and reputational.

Jeremy: And those risks aren’t evenly distributed.

Hamish: How so?

Jeremy: If a system misses a time target, that failure is visible, reportable, and often attributed to frontline teams.

Hamish: But if a system rushes activation inappropriately, the cost is diffuse, extra cath lab use, downstream complications, and opportunity cost.

Jeremy: And diffuse costs rarely trigger the same response.

Hamish: So time targets can unintentionally incentivise over-activation.

Jeremy: Or at least discourage careful hesitation.

Hamish: Which brings us back to the central theme: judgment.

Jeremy: Time targets don’t reward judgment. They reward speed.

Hamish: Unless judgment is explicitly built into how those targets are interpreted and audited

Jeremy: And that’s the missing piece in many systems.

Hamish: The guideline sets targets, but it can’t control how organisations respond to them.

Jeremy: If missed targets are treated as individual failures, clinicians will behave defensively.

Hamish: If they’re treated as design failures, systems improve.

Jeremy: But that distinction requires leadership maturity.

Hamish: It also requires honesty about capacity.

Jeremy: Because some systems simply can’t meet these targets consistently — and pretending they can shifts pressure downstream.

Hamish: Often onto EDs.

Jeremy: Which is why time targets need to be accompanied by explicit statements about shared responsibility.

Hamish: Otherwise, they become another way clinicians absorb system failure.

Jeremy: And another source of moral injury.

Hamish: Let's move on to Secondary Prevention. Secondary prevention is usually framed as something that happens later — on the ward, in the clinic, or after discharge.

Jeremy: Which allows emergency departments to mentally outsource it.

Hamish: But the guideline makes it clear that this is no longer defensible.

Jeremy: Because the first few hours of ACS care quietly determine everything that follows.

Hamish: Not through prescribing per se — but through framing.

Jeremy: Exactly. How a patient is labelled, documented, and communicated about in the ED shapes downstream decisions far more than we like to admit.

Hamish: If the ED frames the event as “troponin-positive chest pain”, the system behaves one way.

Jeremy: If it’s framed as “probable occlusion MI”, it behaves very differently.

Hamish: And that framing starts with ED notes, ED conversations, and ED handover.

Jeremy: Which is why secondary prevention failures are often continuity failures, not pharmacology failures.

Hamish: Unclear documentation leads to ambiguous plans.

Jeremy: Ambiguous plans lead to inconsistent therapy.

Hamish: And inconsistency accumulates harm over time.

Jeremy: The guideline’s more aggressive lipid targets and structured antithrombotic durations are a signal of that thinking.

Hamish: Not that EDs should be managing long-term lipid therapy — but that early intent matters.

Jeremy: Because when intent is vague, inertia wins.

Hamish: There’s also a system memory problem here.

Jeremy: Explain that.

Hamish: EDs are where stories begin, but not where they’re remembered.

Jeremy: So if the ED doesn’t clearly articulate risk and rationale, that context is often lost by the time the patient reaches outpatient care.

Hamish: Which means downstream clinicians inherit uncertainty they didn’t create.

Jeremy: And they respond by hedging.

Hamish: Which undermines the very prevention the guideline is trying to strengthen.

Jeremy: So secondary prevention isn’t about EDs doing more — it’s about EDs being clearer.

Hamish: Clear about the diagnosis. Clear about uncertainty. Clear about intent.

Jeremy: Because clarity travels. Ambiguity doesn’t.

Hamish: And again, this comes back to ownership.

Jeremy: If EDs don’t see themselves as trajectory-setters, no one else will fill that gap reliably.

Hamish: Which is why this section of the guideline matters more than it looks.

Jeremy: It’s less about drugs and more about memory.

Hamish: So let’s bring this out of theory and into Monday morning.

Jeremy: Because this guideline doesn’t fail or succeed on publication. It succeeds or fails on the decisions leaders make next week.

Hamish: And the first thing to be clear about is that updating a pathway is the smallest part of the work.

Jeremy: Exactly. Pathways are the easy bit. They give the illusion of action.

Hamish: What actually matters is what sits behind them.

Jeremy: Leaders have to decide who owns deviation.

Hamish: That sounds abstract, but it’s not.

Jeremy: If a clinician overrides a troponin pathway because they’re worried about occlusion, who backs that call?

Hamish: Is it written into governance? Is it defensible at an audit? Is it supported publicly if outcomes are poor?

Jeremy: Or does that clinician find themselves alone in a morbidity meeting, being asked why they didn’t “just follow the pathway”?

Hamish: Because the answer to that question will determine behaviour far more than any education session.

Jeremy: The second decision is about the audit.

Hamish: Audit sounds neutral, but it’s not.

Jeremy: What you choose to measure tells clinicians what you actually value.

Hamish: If audits only ask whether pathways were followed, clinicians will follow pathways.

Jeremy: If audits ask whether occlusion was reasonably considered, behaviour changes.

Hamish: The third decision is about escalation thresholds.

Jeremy: Who defines them? Who owns them? And who is allowed to activate them when the picture is ambiguous?

Hamish: If escalation is tightly controlled but judgment is expected, you’ve created a contradiction.

Jeremy: And contradictions get resolved at the bedside — usually in the safest way for the individual, not the patient.

Hamish: There’s also a workforce dimension here.

Jeremy: Absolutely. Guidelines that increase cognitive and emotional load without redistributing responsibility accelerate burnout.

Hamish: Especially in departments already running close to the edge.

Jeremy: So leaders have to ask themselves a hard question.

Hamish: Are we genuinely willing to own the uncertainty this guideline introduces?

Jeremy: Or are we implicitly asking clinicians to absorb it on our behalf?

Hamish: Because if it’s the latter, implementation will quietly fail.

Jeremy: Not through rebellion — but through risk-avoidant compliance.

Hamish: And the final decision is cultural.

Jeremy: Does your organisation treat judgment as something to be protected — or something to be tolerated?

Hamish: Because culture isn’t what’s written in the guideline.

Jeremy: It’s what happens when something goes wrong.

Hamish: So as we come to the end of this, it’s worth being very clear about what this episode — and this guideline — actually are.

Jeremy: They’re not primarily about ECG interpretation, troponin kinetics, or cath lab activation criteria.

Hamish: Those are the visible parts. The technical surface.

Jeremy: What’s really being tested here is whether health systems are willing to evolve beyond safety-through-algorithms.

Hamish: Because algorithms are comfortable. They’re clean. They’re auditable.

Jeremy: And they allow organisations to believe that safety is something you can standardise and distribute evenly.

Hamish: The 2025 ACS Guidelines quietly say that’s no longer enough.

Jeremy: They say that in some of the most time-critical decisions we make, safety depends on judgment.

Hamish: Judgement that’s exercised early, under pressure, and in uncertainty.

Jeremy: And judgment is messy.

Hamish: It doesn’t fit neatly into dashboards.

Jeremy: It doesn’t always look right in hindsight.

Hamish: And it requires trust — not just in individuals, but in systems.

Jeremy: Which brings us back to the central question we’ve been circling all episode.

Hamish: When judgment is required, who actually carries the risk?

Jeremy: If the answer is “the clinician alone”, then this guideline will quietly fail.

Hamish: Not because clinicians don’t understand it.

Jeremy: But because they’ll adapt in the only way that keeps them safe.

Hamish: If, however, systems are willing to own uncertainty…

Jeremy: …to protect good-faith judgement…

Hamish: …and to align governance, audit, and culture with what this guideline actually asks…

Jeremy: …then this document has the potential to meaningfully change care.

Hamish: Not by making clinicians smarter.

Jeremy: But by making systems braver.

Hamish: So this isn’t really a cardiology guideline.

Jeremy: And it isn’t just an emergency medicine problem.

Hamish: It’s a leadership test.

Jeremy: Whether we’re willing to design systems that support judgment, rather than quietly punishing it.

Hamish: And that’s a question every organisation has to answer for itself.

Jeremy: Well...it looks like we're out of time! That was a bit of a discussion. Thank you all for tuning in. Catch you in the next episode. Stay safe.

Hamish: Goodbye!